Compounded semaglutide and brand name semaglutide are not two versions of the same medicine. Ozempic and Wegovy are FDA approved, meaning the agency reviewed their safety, effectiveness and manufacturing quality before they reached patients. Compounded semaglutide has never been FDA approved. It became widely available only because a national shortage temporarily let pharmacies make copies of a drug patients could not otherwise get. The FDA declared that shortage resolved on February 21, 2025, and the legal basis for routinely compounding semaglutide copies ended with it. If you are still being offered compounded semaglutide in Florida as a standard, off the shelf option, that deserves a direct question.

What compounding is, and what it is not

Compounding is a licensed pharmacy or physician preparing a medication for one specific patient. It exists for good reasons: someone who reacts to a preservative, or who needs a strength that is not manufactured, may genuinely need one.

What compounding is not is a generic. A generic is approved only after the manufacturer proves equivalence to the brand, and there is no generic semaglutide in the United States. Compounded semaglutide bypasses approval entirely, so no one reviewed that specific product for safety, effectiveness or quality before it was sold. That is the FDA’s own description, not a competitor’s talking point.

Why it became common, and why that ended

Semaglutide sat on the FDA shortage list from 2022. Federal law loosens the copying restrictions while a drug is in shortage, and that opening is what let compounded semaglutide be sold at scale, mostly through telehealth platforms. The FDA closed it in stages:

February 21, 2025. The FDA determined the semaglutide injection shortage was resolved.
April 22, 2025. End of FDA’s stated enforcement discretion for pharmacies and physicians compounding under section 503A.
May 22, 2025. The same window closed for outsourcing facilities under section 503B.

Those dates come from the FDA’s running update for compounders, which in April 2026 noted that semaglutide and tirzepatide appear on neither the 503B bulks list nor the shortage list, the two routes that would let an outsourcing facility compound them from bulk ingredient.

The FDA has since proposed to leave all three of semaglutide, tirzepatide and liraglutide off that bulks list permanently, finding no clinical need. That proposal went out for comment and the period was later extended. At the time of writing no final determination had been issued, so it is a proposal, not settled law.

The narrow door that is still open

Here is where “it is all illegal now” is too simple.

Under section 503A a pharmacy still may not regularly compound a product that is essentially a copy of a commercially available drug, meaning the same active ingredient at the same, similar or easily substitutable strength, given by the same route. The exception is narrow: a prescriber has to determine and document that the compounded version contains a change producing a significant difference for one identified individual patient.

Two consequences rarely make it into the sales pitch. Adding B12 does not automatically make it a different drug, since the FDA has said it may still treat a semaglutide plus vitamin B12 injection as essentially a copy when the amounts sit within 10 percent of the commercial strengths. And volume matters: the FDA has stated it does not intend to act against a compounder filling four or fewer prescriptions of such a product in a calendar month, which is a narrow enforcement posture rather than a license to run a compounded GLP-1 business.

A genuinely patient specific, documented exception is real medicine. A clinic offering compounded semaglutide to everyone who walks through the door is not operating inside it.

What the FDA has actually seen

All of the following comes from the FDA’s concerns with unapproved GLP-1 drugs page.

Salt forms. Some compounded products have used semaglutide sodium or semaglutide acetate. These are different active ingredients from the one in the approved drugs, and the FDA says it is not aware of any lawful basis for their use in compounding.
Dosing errors. The FDA has received reports of adverse events, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide, by patients and in some cases by clinicians miscalculating the dose. A compounded vial is drawn up by hand, unlike the metered pen of the approved product.
Adverse event reports. As of May 31, 2026 the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 for compounded tirzepatide. It notes these are likely underreported, since state licensed pharmacies that are not outsourcing facilities need not report to the FDA.
Shipping and fraud. Injectable GLP-1 drugs need refrigeration, and the FDA has had complaints of product arriving warm. It is also aware of compounded semaglutide and tirzepatide sold with false labels, including labels naming compounding pharmacies that do not exist.
Retatrutide and cagrilintide. Neither can lawfully be used in compounding, and neither has been found safe and effective for any condition. Anything sold “for research purposes” but shipped with dosing instructions is not a treatment.

Red flags, and when to call a clinician instead

The FDA lists warning signs for a telehealth seller: claiming the compounded drug is the same as the FDA approved one, prices that seem too good to be true, no screening or prescription from a licensed clinician, nobody available to answer questions afterwards, and damaged packaging, missing instructions or spelling errors on the label.

Separately, seek medical care rather than adjusting a dose yourself if you have severe abdominal pain, particularly pain that bores through to your back, persistent vomiting or signs of dehydration, or right upper abdominal pain with fever. New or changing vision problems in someone with diabetes also warrant prompt review. These apply to any GLP-1, approved or compounded, and we cover them in GLP-1 side effects.

What to ask before you start

Ask which product is being prescribed and whether it is FDA approved. If it is compounded, ask what documented clinical reason makes it different for you personally, which pharmacy makes it, and whether that pharmacy is state licensed. A clinician who cannot answer those plainly has given you your answer.

If you are choosing between molecules rather than sources, our comparison of semaglutide, tirzepatide and retatrutide covers what each is approved for. Our medical weight loss team sees patients in Deerfield Beach and by telehealth across Florida, in English, Portuguese and Spanish.

Medically reviewed by Krishna Borges, MSN, APRN, FNP-C. This article is for general education and is not a substitute for individual medical advice.